

Supplementary Table 1 - Baseline characteristics of the CrAg-positive and CrAg-negative patients enrolled in the prospective study and screened for TB at the time of enrolment using urine and sputum-based tests

	CrAg+ n=67	CrAg- n=134	P
Age (median, IQR)	39 (32-47)	39 (33-48)	0.63*
Female (%)	37 (55)	62 (46)	0.23
Self-assigned Black race (%)	66 (99)	128 (96)	0.4
Born outside of SA ¹ (%)	28 (42)	33 (25)	0.01
Non-SADC (%)	3 (5)	3 (2)	0.4
CD4 cells/ μ L (median, IQR)	27 (7-40)	41 (16-64)	0.002*
<50 (%)	55(82)	80 (60)	0.001
BMI <18 kg/m ² (%) ²	9 (20)	20(18)	1.0**
Hemoglobin \leq 8g/dl (%) ³	5 (9)	13 (11)	0.8**
CRP mg/L (median, IQR) ⁴	15 (3-49)	22 (4-56)	0.4
Active TB at enrolment [†] (%)	18 (27)	33 (25)	0.6
Previous TB [‡] (%)	11 (16)	14 (10)	0.3**
Other previous or current ADI (%)	11 (16)	20 (15)	0.8**
Histoplasmosis ⁵	3 (5)	3 (2)	0.4**
Other (non-ADI) medical conditions (%)	30 (45)	57 (43)	0.8
Infectious disease (%)	18 (27)	39 (29)	0.7
Hepatitis B ⁶	6 (17)	11 (13)	0.6**
Immunocompromising (%)	2 (3)	4 (3)	1.0**
Taking ART (>1 day) (%)	16 (24)	13 (10)	0.01**
Taking co-trimoxazole (%)	37 (55)	32 (24)	<0.001
Taking other antibiotics (%)	22 (33)	37 (28)	0.4

Abbreviations: CrAg = cryptococcal antigen; IQR = interquartile range; SA = South Africa; SADC = Southern Africa Development Community; CD4 = CD4 T-lymphocyte count; ART = antiretroviral therapy; BMI = body mass index; CRP= C-reactive protein; TB = tuberculosis; ADI = AIDS defining illness.

†Active TB includes those diagnosed with TB within past 6 months and/or on current tuberculosis treatment at enrolment (CrAg+ n= 8/67 (12%), CrAg- n=12/134 (9%)), and those diagnosed on the day of enrolment (CrAg+ n=10/59 (17%), CrAg- n=21/122 (17%)). Diagnoses of TB were made clinically or on the basis of routine laboratory tests, or screening performed as part of the study.

‡Previous TB includes those who were diagnosed more than 6 months prior to enrolment, and who do not remain on tuberculosis treatment.

Data missing on: birthplace for 1 patient¹; BMI for 20 CrAg-positive and 23 CrAg-negative patients²; hemoglobin for 12 CrAg-positive and 15 CrAg-negative patients³; CRP for 5 CrAg-positive and 5 CrAg-negative patients⁴; histoplasmosis screening (urine enzyme immunoassay) for 1 CrAg-positive and 7 CrAg-negative patients⁵; hepatitis B for 32 CrAg-positive and 50 CrAg-negative patients⁶.

* Mann-Whitney U test

** Fisher's Exact Test

Pearson's chi square test used unless indicated.